11560 Federal Register / Vol. 77, No. 38 / Monday, February 27, 2012 / Notices 

Outcome information to be collected 

includes measures of agency-funded 

research resulting in dissemination of 

findings, investigator career 

development, grant-funded knowledge 

and products, commercial products and 

drugs, laws, regulations and standards, 

guidelines and recommendations, 

information on patents and new drug 

applications and community outreach 

and public awareness relevant to 

extramural research funding and 

emerging areas of research. Satisfaction 

information to be collected includes 

measures of satisfaction with the type of 

funding or program management 

mechanism used, challenges and 

benefits with the program support 

received, and gaps in the research. 

Frequency of Response: Once per 

grantee, per NIEHS research portfolio. 

Affected Public: Current or past NIEHS 

grantees. Type of Respondents: 

Principal Investigators with current or 

past NIEHS research or training grants. 

The annual reporting burden is as 

follows: Estimated Number of 

Respondents: 600; Estimated Number of 

Responses per Respondent: 1; Average 

Burden Hours per Response: .5 (30 

minutes); and Estimated Total Annual 

Burden Hours Requested: 100. The 

annualized cost to respondents is 

estimated at: Approximately $17. There 

are no Capital Costs to report. There are 

no Operating or Maintenance Costs to 

report. 

(Note: The following table is acceptable for 

the Respondent and Burden Estimate 

information, if appropriate, instead of the 

text as shown above.) 

Type of respondents 

Estimated 

number of 

respondents 

Estimated 

number of 

responses per 

respondent 

Average 

burden hours 

per response 

(min.) 

Estimated total 

annual burden 

hours 

requested 

NIEHS Grantee ................................................................................................ 600 1 30 100 

Request for Comments: Written 

comments and/or suggestions from the 

public and affected agencies are invited 

on one or more of the following points: 

(1) Whether the proposed collection of 

information is necessary for the proper 

performance of the function of the 

agency, including whether the 

information will have practical utility; 

(2) The accuracy of the agency’s 

estimate of the burden of the proposed 

collection of information, including the 

validity of the methodology and 

assumptions used; (3) Ways to enhance 

the quality, utility, and clarity of the 

information to be collected; and (4) 

Ways to minimize the burden of the 

collection of information on those who 

are to respond, including the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

Direct Comments to OMB: Written 

comments and/or suggestions regarding 

the item(s) contained in this notice, 

especially regarding the estimated 

public burden and associated response 

time, should be directed to the: Office 

of Management and Budget, Office of 

Regulatory Affairs, OIRA_submission@

omb.eop.gov or by fax to 202–395–6974, 

Attention: Desk Officer for NIH. To 

request more information on the 

proposed project or to obtain a copy of 

the data collection plans and 

instruments, contact 

Dr. Kristianna Pettibone, Evaluator, 

Program Analysis Branch, NIEHS, NIH, 

530 Davis Dr., Room 3055, Morrisville, 

NC 20560, or call non-toll-free number 

919–541–7752 or email your request, 

including your address to: 

pettibonekg@niehs.nih.gov. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 30-days of the date of 

this publication. 

Dated: February 16, 2012. 

Joellen M. Austin, 

Associate Director for Management, NIEHS, 

National Institutes of Health. 

[FR Doc. 2012–4543 Filed 2–24–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301– 

496–7057; fax: 301–402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Model Cell Lines With and Without 

AKT1 Mutations Derived From Proteus 

Syndrome Patients 

Description of Technology: The 

Proteus syndrome is a congenital 

disorder characterized by patchy 

overgrowth and hyperplasia (cell 

proliferation) of multiple tissues and 

organs, along with susceptibility to 

developing tumors. It is a rare disorder, 

with incidence of less than one case per 

million, caused by a somatic mutation. 

It is also a mosaic disorder, that is one 

in which cells of the same person have 

different genetic content from one 

another. The NHGRI inventors have 

generated cell lines from patients with 

Proteus syndrome and discovered that a 

somatic activating mutation in the 

serine-threonine kinase AKT1 is 

associated with Proteus syndrome. 

AKT1 is an oncogene and an enzyme 

known to mediate cell proliferation and 

apoptosis (programmed cell death 

process) and has been a target for anticancer therapies. A number of singlecell lines with the AKT1 mutation 

showing increased AKT1 

phosphorylation and their matched 

controls without the mutation have been 

generated. The cell lines can be used to 

screen therapeutic targets for AKT1, for 

study design, as models of Proteus 

syndrome and early stages of cancerous 

conditions. 

Potential Commercial Applications 

• Cell lines generated from patients 

with Proteus syndrome. 

• Obtained a number of single-cell 

lines with the AKT1 mutation and their 

matched controls without the mutation. 


srobinson on DSK4SPTVN1PROD with NOTICES
Federal Register / Vol. 77, No. 38 / Monday, February 27, 2012 / Notices 11561 

• Cell lines with the mutation 

showed increased AKT1 

phosphorylation for activating mutation. 

Competitive Advantages 

• Screening of potential therapeutics 

that target AKT1. 

• Cell lines have well-matched 

controls for rigorous study design. 

• Serves as model cell lines of 

Proteus syndrome and early stages of 

cancerous conditions. 

Development Stage 

• Prototype. 

• Clinical. 

• In vivo data available (human). 

Inventors: Leslie G. Biesecker and 

Marjorie J. Lindhurst (NHGRI). 

Publication: Lindhurst MJ, et al. A 

mosaic activating mutation in AKT1 

associated with the Proteus syndrome. 

N Engl J Med. 2011 Aug 18;365(7):611– 

619. [PMID 21793738]. 

Intellectual Property: HHS Reference 

No. E–033–2012/0 — Research Tool. 

Patent protection is not being pursued 

for this technology. 

Licensing Contact: Whitney Hastings, 

Ph.D.; 301–451–7337; 

hastingw@mail.nih.gov 

Non-toxic Compounds That Inhibit the 

Formation and Spreading of Tumors 

Description of Technology: Available 

for licensing are novel 

pyrrolopyrimidine compounds that 

disrupt the assembly of the 

perinucleolar compartment (PNC), a 

sub-nuclear structure highly prevalent 

in metastatic tumors. These notable 

compounds act without overt 

cytotoxicity. 

The presence of the PNC positively 

correlates with metastatic capacity, 

making it a potential marker for cancer 

development and prognosis. These 

compounds could also serve as useful 

tools to elucidate the biology driving the 

formation and maintenance of the PNC, 

and unravel its association with 

metastasis. 

Potential Commercial Applications 

• Use in the therapeutic intervention 

of metastasis in cancer. 

• Use as tools to elucidate the biology 

of the PNC. 

Competitive Advantages 

• No existing FDA-approved 

treatment for the clinical management of 

metastasis. 

• Target is specific to metastatic 

tumors. 

• Compounds are not toxic. 

• Broadly acting across all metastatic 

cancers. 

Development Stage 

• Early-stage. 

• In vitro data available. 

Inventors: Samarjit Patnaik et al. 

(NCATS). 

Intellectual Property: HHS Reference 

No. E–276–2011/0 — U.S. Provisional 

Application No. 61/576,780 filed 16 Dec 

2011. 

Licensing Contact: Patrick McCue, 

Ph.D.; 301–435–5560; 

mccuepat@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Center for Advancing 

Translational Sciences is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate or 

commercialize this technology. For 

collaboration opportunities, please 

contact Lili M. Portilla, MPA at 301– 

217–2589 or Lilip@nih.gov. 

Novel Radio-Labeled Agents for 

Imaging Alzheimer’s DiseaseAssociated Amyloid 

Description of Technology: This 

technology introduces novel radiolabeled agents for imaging amyloid 

deposits in the brains of Alzheimer’s 

Disease patients. These are small 

molecule, radio-ligand compounds that 

are analogs of benzo[d]thiazole. They 

are highly specific to amyloid, have low 

background noise, do not undergo rapid 

defluoridation and do not produce 

residual radioactivity in the brain. In 

addition, the compounds are stable and 

may be readily synthesized from 

commercially available starting 

materials. These compounds may be 

used in many noninvasive imaging 

techniques including: magnetic 

resonance spectroscopy (MRS) or 

imaging (MRI), or positron emission 

tomography (PET) or single-photon 

emission computed tomography 

(SPECT) to measure amyloid. Noninvasive detection of Alzheimer’s 

disease-associated amyloid plaques in 

the brain would be valuable for early 

diagnosis, monitoring, and for clinical 

development of therapeutic drugs. 

Potential Commercial Applications: 

Imaging agents for use in magnetic 

resonance spectroscopy (MRS), or 

imaging (MRI), positron emission 

tomography (PET) or single-photon 

emission computed tomography 

(SPECT). 

Competitive Advantages: Highly 

specificity to amyloid, low background, 

do not undergo rapid defluoridation and 

do not produce residual radioactivity in 

the brain. 

Development Stage: Early-stage. 

Inventors: Lisheng Cai and Victor W. 

Pike (NIMH). 

Publications 

1. Cai L, et al. Synthesis and 

structure-affinity relationships of new 4- 

(6-iodo-H-imidazo[1,2-a]pyridin-2-yl)-Ndimethylbenzeneamine derivatives as 

ligands for human beta-amyloid 

plaques. J Med Chem. 2007 Sep 

20;50(19):4746–4758. [PMID 17722900]. 

2. Cai L, et al. Synthesis and 

evaluation of N-methyl and S-methyl 

11C-labeled 6-methylthio-2-(4’-N,Ndimethylamino)phenylimidazo[1,2- 

a]pyridines as radioligands for imaging 

beta-amyloid plaques in Alzheimer’s 

disease. J Med Chem. 2008 Jan 

10;51(1):148–158. [PMID 18078311]. 

Intellectual Property: HHS Reference 

No. E–225–2011/0—U.S. Provisional 

Application No. 61/535,569 filed 16 Sep 

2011. 

Related Technology: HHS Reference 

No. E–156–2006/0—U.S. Patent 

Application No. 12/293,340 filed 17 Sep 

2008. 

Licensing Contact: Tedd Fenn, J.D.; 

301–435–5031; Tedd.Fenn@nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Mental Health 

(NIMH) is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate or 

commercialize Beta-amyloid Imaging 

Agents. For collaboration opportunities, 

please contact Suzanne L. Winfield, 

Ph.D. at winfiels@intra.nimh.nih.gov or 

301–402–4324. 

A New Class of Broad-Spectrum 

Antibiotics: Naturally-Occurring 

Chrysophaetins and Their Analogues 

Description of Technology: This 

invention, offered for licensing and 

commercial development, relates to a 

new class of naturally occurring 

antimicrobial compounds called 

Chrysophaetins, and to their synthetic 

analogues. Isolated from an alga species, 

the mechanism of action of these 

compounds is through the inhibition of 

bacterial cytoskeletal protein FtsZ, an 

enzyme necessary for the replication of 

bacteria. FtsZ is responsible for Z-ring 

assembly in bacteria, which leads to 

bacterial cell division. Highly conserved 

among all bacteria, FtsZ is a very 

attractive antimicrobial target. 

The chrysophaetin exhibits 

antimicrobial activity against drug 

resistant bacteria, methicillin-resistant 

Staphylococcus aureus (MRSA) and 

vancomycin-resistant Enterococcus 

faecalis (VRE), as well as other drug 

susceptible strains. The general 

structure of the natural compound is 

shown below: 


srobinson on DSK4SPTVN1PROD with NOTICES
11562 Federal Register / Vol. 77, No. 38 / Monday, February 27, 2012 / Notices 

Potential Commercial Applications 

• Therapeutic potential for treating 

general and drug-resistant bacterial 

infections in clinical and veterinary 

populations. 

• Antiseptics in hospital settings. 

Competitive Advantages 

• Effective for commonly occurring 

drug-resistant infections MRSA and 

VRE. 

• Broad spectrum of efficacy because 

mechanism of action is against the 

bacterial protein FtsZ, which has similar 

structure in all bacteria. 

• Potential for additive efficacy when 

combined with other antibiotics due to 

distinct mechanism of action. 

• Other drugs with similar structure 

and antibacterial properties can be 

synthesized using the chemical 

structure template shown above. 

Development Stage 

• Early-stage. 

• In vitro data available. 

Inventors: Carole A Bewley, et al. 

(NIDDK). 

Publication: Plaza A, et al. 

Chrysophaentins A–H, antibacterial 

bisdiarylbutene macrocycles that inhibit 

the bacterial cell division protein FtsZ. 

J Am Chem Soc. 2010 Jul 

7;132(26):9069–9077. [PMID 20536175]. 

Intellectual Property: HHS Reference 

No. E–116–2010/0—PCT Application 

No. PCT/US2011/026200 filed 25 Feb 

2011, which published as WO 2011/ 

106630 on 01 Sep 2011. 

Licensing Contact: John Stansberry, 

Ph.D.; 301–435–5236; 

stansbej@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Diabetes and 

Digestive and Kidney Diseases, 

Laboratory of Bioorganic Chemistry, is 

seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate, or commercialize the 

chrysophaentin antibiotics. Please 

contact Marguerite J. Miller at 301–451– 

3636 or millermarg@niddk.nih.gov for 

more information. 

Dated: February 21, 2012. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2012–4376 Filed 2–24–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of General Medical 

Sciences; Notice of Closed Meeting 

Pursuant to Section 10(d) of the 

Federal Advisory Committee Act, as 

Amended (5 U.S.C. App.), Notice Is 

Hereby Given of the Following 

Meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

General Medical Sciences Special Emphasis 

Panel Review of Minority Biomedical 

Research Support Genetics Applications. 

Date: March 19–20, 2012. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency—Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Saraswathy Seetharam, 

Ph.D., Scientific Review Officer, Office of 

Scientific Review, National Institute of 

General Medical Sciences, National Institutes 

of Health, 45 Center Drive, Room 3An12C, 

Bethesda, MD 20892, 301–594–2763, 

seetharams@nigms.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.375, Minority Biomedical 

Research Support; 93.821, Cell Biology and 

Biophysics Research; 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.862, Genetics and 

Developmental Biology Research; 93.88, 

Minority Access to Research Careers; 93.96, 

Special Minority Initiatives, National 

Institutes of Health, HHS) 

Dated: February 21, 2012. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2012–4526 Filed 2–24–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Deafness and 

Other Communication Disorders; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 

U.S.C., as amended. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: National Institute on 

Deafness and Other Communication 

Disorders Special Emphasis Panel P30 

Review 

Date: March 28, 2012. 

Time: 12:30 p.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6120 

Executive Blvd., Rockville, MD 20852 

(Telephone Conference Call). 

Contact Person: Christine A. Livingston, 

Ph.D. Scientific Review Officer, Division of 

Extramural Activities, National Institutes of 

Health/NIDCD, 6120 Executive Blvd.—MSC 

7180, Bethesda, MD 20892, (301) 496–8683, 

livingsc@mail.nih.gov. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

www.nidcd.nih.gov/about/groups/sep/, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.173, Biological Research 

Related to Deafness and Communicative 

Disorders, National Institutes of Health, HHS) 

Dated: February 21, 2012. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2012–4535 Filed 2–24–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of General Medical 

Sciences; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 


srobinson on DSK4SPTVN1PROD with NOTICESEN27FE12.009</GPH>